Guardian Point Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Guardian Point Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-511,972	Closed	-$1.83M	–	21
2020 Q2	$1.83M	Buy	+511,972	New	+$1.85M	0.67%	20
2020 Q1	–	Sell	-1,200,000	Closed	-$3.61M	–	18
2019 Q4	$3.61M	Buy	+1,200,000	New	+$3.12M	1.21%	15

Other funds holding BMY.RT

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Guardian Point Capital's BMY.RT Position: Q3 2020 in Review

Guardian Point Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q3 2020, closing a stake of 511,972 shares — an estimated $1.83M sold.

Guardian Point Capital first reported a position in BMY.RT in Q4 2019 and held it in 2 quarters. The position peaked at $3.61M in Q4 2019. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

Guardian Point Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q3 2020 after selling out during the quarter.
Guardian Point Capital sold 511,972 Bristol-Myers Squibb Company Contingent Value Rights shares in Q3 2020, an estimated $1.83M.
Guardian Point Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 2 quarters.
Guardian Point Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $3.61M in Q4 2019.
571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on Guardian Point Capital's 13F filing for Q3 2020, filed 16 Nov 2020.